Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.

BACKGROUND: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether an MVA which does not encode any antigen (Ag) could...

Full description

Bibliographic Details
Main Authors:	Miriam Nörder, Pablo D Becker, Ingo Drexler, Claudia Link, Volker Erfle, Carlos A Guzmán
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2010-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC2900180?pdf=render

Similar Items

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
by: Caroline Staib, et al.
Published: (2003-04-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
by: C. Staib, et al.
Published: (2000-06-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitopes
by: Pablo D. Becker, et al.
Published: (2014-07-01)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Expression of an Efficient Selection Marker Out of a Duplicated Site in the ITRs of a Modified Vaccinia Virus Ankara (MVA)
by: Sirine Abidi, et al.
Published: (2024-12-01)

Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway.
by: Peihong Dai, et al.
Published: (2014-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
by: Mingwang Shen, et al.
Published: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
by: Sonia T Wennier, et al.
Published: (2013-01-01)

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.
by: Felipe Tapia, et al.
Published: (2017-01-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
by: Moorthy, V, et al.
Published: (2003)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
by: López-Camacho, C, et al.
Published: (2019)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
by: César López-Camacho, et al.
Published: (2019-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
by: Juan García-Arriaza, et al.
Published: (2021-08-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
by: David A Garber, et al.
Published: (2009-01-01)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
by: Alexandra Kupke, et al.
Published: (2022-03-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
by: Valentina Mazzotta, et al.
Published: (2024-12-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
by: Asisa Volz, et al.
Published: (2018-01-01)

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
by: Sharpe, S, et al.
Published: (2001)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
by: Alharbi, N, et al.
Published: (2015)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
by: Schmidt, C, et al.
Published: (2008)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
by: L. F. Stovba, et al.
Published: (2023-04-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
by: Flavia Chiuppesi, et al.
Published: (2024-02-01)

Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection
by: Jonas D. Albarnaz, et al.
Published: (2023-12-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
by: Franziska Tanneberger, et al.
Published: (2021-10-01)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
by: Lioba Klaas, et al.
Published: (2021-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
by: Naif Khalaf Alharbi, et al.
Published: (2015-01-01)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
by: Arwen F. Altenburg, et al.
Published: (2017-08-01)